Optogenetic Gene Therapy Well Tolerated For Retinitis Pigmentosa

Source: HCP Live

New findings presented on ARVOLearn showed that an optogenetic gene therapy was well tolerated in a group of patients with end-stage non-syndromic retinitis pigmentosa, according to a report by HCP Live.

The findings were published on ARVOLearn due to the cancellation of the 2020 Association for Research in Vision and Ophthalmology (ARVO) annual meeting. At the time of the study, there were no good therapies for retinitis pigmentosa, principal investigator Joseph Martel, MD, said during the presentation.

Read the full article.

Related Content